Thermo Fisher Scientific Inc header image

Thermo Fisher Scientific Inc

TMO

Equity

ISIN US8835561023 / Valor 977576

New York Stock Exchange, Inc (2024-10-24)
USD 557.38-3.31%

Thermo Fisher Scientific Inc
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Thermo Fisher Scientific Inc. is a global leader in providing innovative technologies, purchasing convenience, and pharmaceutical services to enable customers to make the world healthier, cleaner, and safer. With annual revenue exceeding $40 billion, the company's diverse portfolio includes brands such as Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. Thermo Fisher serves a wide range of industries, from life sciences research to diagnostics and therapies, offering solutions to complex analytical challenges and increasing productivity in laboratories worldwide. With a team of over 90,000 colleagues, Thermo Fisher Scientific is dedicated to supporting its customers in their mission to drive scientific advancements and improve global health outcomes.

Summarized from source with an LLMView SourceSector: Technology

Latest Results (07.08.2024):

Revenue Growth

Thermo Fisher Scientific Inc. reported total revenues of $10.54 billion for the second quarter of 2024. This represents a slight decrease compared to the $10.69 billion reported in the same quarter of the previous year. The revenue was driven by both product and service sales, with product revenues contributing $6.16 billion and service revenues contributing $4.38 billion.

Net Income

For the second quarter of 2024, Thermo Fisher Scientific Inc. achieved a net income of $1.55 billion. This is an increase from the $1.36 billion net income reported in the second quarter of 2023. The increase in net income reflects the company's effective cost management and operational efficiencies.

Earnings Per Share

Thermo Fisher Scientific Inc. reported earnings per share (EPS) of $4.05 for the second quarter of 2024. This is a slight increase from the EPS of $3.53 reported in the same quarter of the previous year. The diluted EPS for the quarter was $4.04, compared to $3.51 in the second quarter of 2023.

Operating Income

In the second quarter of 2024, Thermo Fisher Scientific Inc. reported an operating income of $1.82 billion. This is a decrease from the $1.58 billion reported in the second quarter of 2023. The operating income was impacted by higher costs and operating expenses, which totaled $8.72 billion for the quarter.

Cash Flow

Thermo Fisher Scientific Inc. generated $3.21 billion in net cash from operating activities during the first six months of 2024. This is an increase from the $2.27 billion generated in the same period of the previous year. The company ended the second quarter with $7.10 billion in cash and cash equivalents, compared to $8.10 billion at the beginning of the year.

Summarized from source with an LLMView Source

Key figures

21.6%1Y
-8.92%3Y
89.9%5Y

Performance

21.4%1Y
25.5%3Y
28.1%5Y

Volatility

Market cap

217200 M

Market cap (USD)

Daily traded volume (Shares)

547,300

Daily traded volume (Shares)

1 day high/low

572.48 / 557.26

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Azenta Inc
Azenta Inc Azenta Inc Valor: 1568240
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.12%USD 40.87
Intellia Therapeutics Inc
Intellia Therapeutics Inc Intellia Therapeutics Inc Valor: 32256913
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.63%USD 15.95
Array Technologies Inc
Array Technologies Inc Array Technologies Inc Valor: 57373259
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
4.38%USD 6.44
Ambarella Inc
Ambarella Inc Ambarella Inc Valor: 19685074
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.77%USD 57.75
MaxLinear Inc
MaxLinear Inc MaxLinear Inc Valor: 11132674
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.59%USD 14.85
Beam Therapeutics Inc
Beam Therapeutics Inc Beam Therapeutics Inc Valor: 50337226
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.44%USD 21.55
Acadia Pharmaceuticals Inc
Acadia Pharmaceuticals Inc Acadia Pharmaceuticals Inc Valor: 1184425
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.97%USD 14.34
TripAdvisor Inc
TripAdvisor Inc TripAdvisor Inc Valor: 14491714
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.13%USD 15.27
Prothena Corporation PLC
Prothena Corporation PLC Prothena Corporation PLC Valor: 20224443
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-5.96%USD 15.30
Kulicke & Soffa Industries Inc
Kulicke & Soffa Industries Inc Kulicke & Soffa Industries Inc Valor: 945945
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.07%USD 44.59